“The bar is high; we want to be curing these patients, not just delaying a recurrence of their cancer,” says Arlene O. Siefker-Radtke, MD.
In this video, Arlene O. Siefker-Radtke, MD, discusses recent developments in the adjuvant treatment of bladder cancer. Siefker-Radtke is a professor of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston. She was interviewed at the 2022 LUGPA Annual Meeting in Chicago, Illinois.
UGN-102 reaches nearly 80% complete response rate in low-grade intermediate-risk NMIBC
November 30th 2023Primary chemoablative therapy with the mitomycin-containing reverse thermal gel UGN-102 induced complete responses in nearly 4 out of 5 patients with low-grade intermediate-risk non–muscle-invasive bladder cancer.